Hypersensitivity Pneumonitis as a Complication of Intravesical BCG Therapy for Bladder Cancer

2016 ◽  
Vol 52 (8) ◽  
pp. 445-446 ◽  
Author(s):  
Laura Carrasco Hernández ◽  
Ángel Luis Castaño Núñez ◽  
José Antonio Rodríguez Portal
Keyword(s):  
Bladder Cancer ◽  
Hypersensitivity Pneumonitis ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy

scholarly journals Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience

2020 ◽  
Vol 26 (1) ◽  
Author(s):  
Vivek Sharma ◽  
Avinash P. S. Thakur ◽  
Vasantharaja Ramasamy ◽  
Pushpendra Kumar Shukla ◽  
Fanindra Singh Solanki ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Adverse Effects ◽  
Bladder Carcinoma ◽  
Bladder Tumour ◽  
The Body ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Urothelial Bladder ◽  
Muscle Invasive ◽  
Intravesical Bcg Therapy

Abstract Background Urothelial bladder carcinoma accounts for around 3.9% cases of all the male cancers in India. Non-muscle-invasive bladder carcinoma (NMIBC) is predominant group which constitute approximately three fourth of the urothelial bladder cancer. Intravesical BCG immunotherapy is the corner stone of today’s NMIBC management. However, as with any other therapy it has its own complications and its interruption due to these adverse effects is a major cause of suboptimal efficacy. The aim of this study was to assess the complications of intravesical BCG therapy and their management in NMIBC patients. Methods This was a retrospective descriptive study conducted between October 2016 and November 2019; a backward review of 149 patients with diagnosis of NMIBC that undergone intravesicle BCG therapy was performed. Patient’s demographical, clinical, diagnostic and procedural data regarding bladder tumour, BCG therapy, its complications and management were collected and analysed. Results Total 149 patients were analysed, comprising 116 males and 33 females. The mean age was of 57.2 ± 6.7 years. Total 85.23% were primary and 14.76% were recurrent tumours. Total 96 patients (64.42%) completed the planned course, while 53 (35.57%) interrupted. The reasons for BCG interruption includes adverse effects (15.4%), progression of disease (6.7%), disease refractory to BCG (4.6%) and disease recurrence during BCG (3.3%). Most of the adverse events occurred in first 6 months and most interruptions occurred after the induction period. Cystitis was the most common observed adverse effect seen in 39.6% patients. Frequency, urgency, haematuria were common presentation. Radical cystectomy was the most common (16.10%) further treatment with patients whose treatment was interrupted. Conclusion BCG is an indispensable therapy available for NMIBC, but it is associated with array of adverse effects and complications, which are the main reasons for poor compliance to BCG therapy. Although BCG-related complications can affect any organ in the body, potentially life-threatening systemic BCG-related infections are encountered in only < 5% of patients. There are some difficulties in diagnosis of the BCG complications because acid-fast staining, culture and PCR test are not always positive; tissue biopsies should be indicated sometimes to evaluate histopathology and presence of M. bovis. A persistently monitored multidisciplinary approach with high index of suspicion and prompt anti-TB therapy can help to derive the maximum benefits while keeping the complications at check.

Granulomatous Hepatitis as a Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report

2010 ◽  
Vol 30 (3) ◽  
pp. 1092-1095
Author(s):  
İbrahim Koral ÖNAL ◽  
Meral AKDOĞAN ◽  
Adalet AYPAK ◽  
Perihan OĞUZ ◽  
Tülay TEMUÇİN KEKLİK ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Case Report ◽  
Rare Complication ◽  
Cancer Case ◽  
Granulomatous Hepatitis ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Bladder Cancer Case ◽  
Intravesical Bcg Therapy

Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer

1998 ◽  
Vol 30 (1) ◽  
pp. 41-44 ◽  
Author(s):  
F. Yalçinkaya ◽  
L. Kamiş ◽  
O. Özteke ◽  
B. Günlüsoy ◽  
O. Yiĝitbasi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Standard Dose ◽  
Low Doses ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy

UP-01.059 Evaluation of the Need for Transuretheral Biopsy at First Follow-Up After Intravesical BCG Therapy for Superficial Bladder Cancer

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S203
Author(s):  
K. Hammoud ◽  
M. Elsheikh ◽  
H. Abdelraouf ◽  
A. Aboumohamed ◽  
Y. Ramadan ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy

Intravesical BCG-Therapy for Superficial Bladder Cancer: Its Effectiveness and Adverse Effects

1996 ◽  
Vol 27 (S 1) ◽  
pp. 51-53
Author(s):  
H. Tanaka ◽  
J. Yoshimasa ◽  
Y. Furukawa ◽  
Y. Arai ◽  
T. Araki
Keyword(s):  
Bladder Cancer ◽  
Adverse Effects ◽  
Superficial Bladder Cancer ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy

scholarly journals Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer

1997 ◽  
Vol 25 (1) ◽  
pp. 31-34 ◽  
Author(s):  
E. C. de Boer ◽  
L. Somogyi ◽  
G. J. W. de Ruiter ◽  
Th. M. de Reijke ◽  
K. -H. Kurth ◽  
...  
Keyword(s):  
Immune Response ◽  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Interleukin 8 ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy

Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer

1994 ◽  
Vol 22 (3) ◽  
pp. 177-184 ◽  
Author(s):  
M. J. J. G. Stassar ◽  
P. D. J. Vegt ◽  
P. A. Steerenberg ◽  
A. P. M. van der Meijden ◽  
H. D. Meiring ◽  
...  
Keyword(s):  
Immune Response ◽  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Local Immune Response ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy
Sign in / Sign up

Export Citation Format

Share Document